DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Leustatin (Cladribine) - Published Studies

 
 



Leustatin Related Published Studies

Well-designed clinical trials related to Leustatin (Cladribine)

Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: Analysis of Economic Data from the CLARITY Study. [2012.01.01]

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. [2011.05]

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). [2010.04.10]

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. [2010.02.04]

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2010.02]

Development of oral cladribine for the treatment of multiple sclerosis. [2010]

Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. [2009.08]

Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. [2009.06]

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). [2006.07.15]

Cladribine for multiple sclerosis: review and current status. [2005.11]

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). [2005.10]

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. [2004.05]

Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. [2003.12]

Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. [2002.10.15]

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. [2001.10]

Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. [2001.01]

Whole brain volume changes in patients with progressive MS treated with cladribine. [2000.12.12]

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. [2000.10.15]

The effect of cladribine on T(1) 'black hole' changes in progressive MS. [2000.05.01]

Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. [2000.03.14]

The cladribine trial in secondary progressive multiple sclerosis: A reanalysis. [2000.03]

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. [2000.02]

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. [2000.02]

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. [1999.01]

[Chronic lymphatic leukemia. Peroral cladribine as primary treatment] [1996.11.04]

Development of cladribine treatment in multiple sclerosis. [1996.07]

The treatment of chronic progressive multiple sclerosis with cladribine. [1996.02.20]

Cladribine in treatment of chronic progressive multiple sclerosis. [1994.07.02]

Well-designed clinical trials possibly related to Leustatin (Cladribine)

Pathogenesis and Treatment of Anti-MAG Neuropathy. [2010.03]

Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. [2006.08]

Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. [2005.11]

New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients. [2000]

Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. [1999.11]

Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. [1999.07]

2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. [1998.01]

A comparison of two neurologic scoring instruments for multiple sclerosis. [1996.03]

The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis. [1996]

The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. [1994]

Treatment of hairy-cell leukemia. [1990.12]

Other research related to Leustatin (Cladribine)

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. [2011.06.16]

Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. [2011.06]

Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. [2011.06]

Development of cladribine at Scripps for hairy cell leukemia and current results. [2011.06]

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. [2011.06]

Alternative methods of cladribine administration. [2011.06]

Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. [2011.06]

Mechanism of action of pentostatin and cladribine in hairy cell leukemia. [2011.06]

Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. [2011.06]

Response to cladribine in patient with systemic mastocytosis. [2011.05]

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. [2011.04]

Cladribine tablets: in relapsing-remitting multiple sclerosis. [2011.03.01]

Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. [2011.02]

Evaluation of Cladribine treatment in refractory celiac disease type II. [2011.01.28]

Cladribine: mode of action and implications for treatment of multiple sclerosis. [2011.01]

Beyond hairy cell: the activity of cladribine in other hematologic malignancies. [2010.10.21]

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. [2010.10.05]

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. [2010.09]

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. [2010.07.21]

[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs] [2010.04]

Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). [2010.04]

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. [2010.03.11]

Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. [2010.03]

Development of oral cladribine for the treatment of multiple sclerosis. [2010.02]

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. [2010.01.01]

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. [2010.01.01]

The cladribine conundrum: deciphering the drug's mechanism of action. [2010.01]

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2010]

Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. [2009.12]

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. [2009.11.19]

Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. [2009.11]

Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. [2009.10]

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more aggressive behavior. [2009.08.10]

Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. [2009.08]

Cladribine: not just another purine analogue? [2009.08]

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2009.07.04]

Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. [2009.07]

[Hairy cell leukemia: Part II: therapy with cladribine] [2009.07]

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. [2009.06]

Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation. [2009.04]

Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. [2009.03]

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. [2009.03]

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. [2009.01.16]

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. [2009.01.01]

Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. [2009]

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. [2008.12]

Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. [2008.11]

Cladribine tablets' potential in multiple: sclerosis treatment. [2008.10]

Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin. [2008.09]

Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. [2008.07.15]

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. [2008.07.01]

Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. [2008.05.09]

Cladribine in indolent non-Hodgkin's lymphoma. [2008.04]

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. [2008.02]

Combined treatment with splenectomy and cladribine in hairy cell leukemia in Taiwan: a clinicopathologic study of 5 cases. [2007.12]

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. [2007.11.15]

[Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia] [2007.11]

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. [2007.11]

[Combination therapy with rituximab and cladribine for patients with follicular lymphoma] [2007.10]

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. [2007.08]

Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. [2007.08]

Cladribine in aggressive forms of multiple sclerosis. [2007.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012